Detail akcie Humacyte Rg online

Business Summary: Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Humacyte Inc revenues increased from $0K to $2M. Net loss decreased 73% to $40.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects bioengineered human tissues segment loss decrease of 5% to $108.1M, United States segment loss decrease of 5% to $108.1M.